Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating whether an AI-powered large language model can help doctors improve the diagnosis of rare or difficult-to-diagnose diseases. This trial compares the use of AI-assisted diagnostic support with standard clinical care to see if it improves diagnostic accuracy, speeds up diagnosis, and affects health-economic outcomes for patients with suspected rare diseases. The study is a multicenter randomized controlled trial involving physicians and patients across various hospitals. Participants are randomly assigned to one of two groups one where doctors use the AI system during patient consultations to organize clinical information, analyze cases, and suggest possible diagnoses, and another group where doctors follow standard diagnostic procedures without AI assistance. Use of other generative AI tools is not allowed in either group. The trial also includes an economic evaluation to track healthcare resources and costs related to the diagnostic process. Participants will have a first consultation with their physician, during which various measures are recorded, including the duration of the consultation and experiences reported by both patients and doctors. Outcomes such as correct diagnostic yield, diagnostic accuracy, time to diagnosis, and appropriate genetic testing recommendations will be evaluated over approximately eight weeks following the initial visit. The study uses blinded independent experts to assess the diagnostic outcomes, and participants are expected to complete structured follow-up during this period.
Actively Recruiting
Researchers are studying whether using a drug-eluting stent DES combined with aggressive medical treatment is more effective at preventing stroke recurrence within one year compared to standard medical treatment alone in patients with symptomatic intracranial atherosclerotic disease. This prospective, multi-center trial randomly assigns participants to either the stent plus aggressive medication group or the standard treatment group to evaluate safety and stroke prevention outcomes. The study compares two groups one receiving the Maurora Sirolimus Eluting Stent implantation plus aggressive medical treatment, which includes aspirin daily throughout follow-up, clopidogrel or ticagrelor for six months, and management of risk factors like hypertension and diabetes the other receiving standard medical treatment with aspirin daily, clopidogrel or ticagrelor for three months, and similar risk factor management. The device used is a balloon-expandable sirolimus-eluting stent delivered via catheter. Follow-up lasts 12 months after enrollment. Participants will undergo regular assessments including monitoring for stroke or death within 30 days after enrollment or procedures, ischemic stroke occurrence up to one year, bleeding events, imaging to check for vessel narrowing, and functional status evaluations. Safety and effectiveness are closely tracked through clinical visits and tests over the 12-month period. The study aims to provide detailed data on stroke recurrence prevention and treatment safety in this patient population.